Tetraphase Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TTPH)

$2.12 -0.08 (-3.64 %)
(As of 02/19/2018 11:06 AM ET)
Previous Close$2.20
Today's Range$2.11 - $2.26
52-Week Range$2.10 - $9.93
Volume1.94 million shs
Average Volume1.10 million shs
Market Capitalization$109.38 million
P/E RatioN/A
Dividend YieldN/A
Beta2.29

About Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

Receive TTPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTPH
CUSIPN/A
Phone617-715-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio7.55%
Quick Ratio7.55%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.14 million
Price / Sales21.28
Cash FlowN/A
Price / CashN/A
Book Value$3.79 per share
Price / Book0.56

Profitability

Trailing EPS($2.86)
Net Income$-77,480,000.00
Net Margins-1,382.33%
Return on Equity-88.27%
Return on Assets-77.53%

Miscellaneous

Employees66
Outstanding Shares51,600,000

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.63). The biopharmaceutical company had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. Tetraphase Pharmaceuticals's revenue was up 355.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.58) earnings per share. View Tetraphase Pharmaceuticals' Earnings History.

When will Tetraphase Pharmaceuticals make its next earnings announcement?

Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Tetraphase Pharmaceuticals.

Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2018?

7 analysts have issued 1 year target prices for Tetraphase Pharmaceuticals' stock. Their forecasts range from $6.00 to $24.00. On average, they anticipate Tetraphase Pharmaceuticals' share price to reach $10.83 in the next twelve months. View Analyst Ratings for Tetraphase Pharmaceuticals.

What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock?

Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock:

  • 1. HC Wainwright analysts commented, "a Highly Favorable Risk/Reward; Affirm Buy Stock Data 02/05/2018 Price $5.19 Exchange NASDAQ Price Target $17.00 52-Week High $9.93 52-Week Low $4.04 Enterprise Value (M) $106.6 Market Cap (M) $268 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 477,304 Short Interest (M) 2.97 Shares Outstanding (M): Figure shown is as of January 24, 2018. Balance Sheet Metrics Cash (M) $161.4 Total Debt (M) $0.0 Total Cash/Share $3.13 Book Value/Share $2.78 Cash (M): Figure shown is as of September 30, 2017. EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.46) (0.79)A (0.56) 2Q (0.47) (0.83)A (0.55) 3Q (0.58) (0.63)A (0.54) 4Q (0.61) (0.60) (0.52) FY (2.11) (2.80) (2.17) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 2.0 1.5A 1.5 2Q 1.2 1.6A 1.0 3Q 0.9 4.1A 1.2 4Q 1.1 2.0 1.5 FY 5.1 9.1 5.2 10 8 6 4 2 FEB- 17 J UN- 17 OCT- 17 FEB- 18 20 15 10 5 0 Vol. (mil) Price cUTI: We believe IGNITE3 will be a solid, clean win." (2/6/2018)
  • 2. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (1/12/2018)

Who are some of Tetraphase Pharmaceuticals' key competitors?

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Chairman of the Board of Directors (Age 74)
  • Guy Macdonald, President and Chief Executive Officer, Director (Age 56)
  • Christopher Watt, Principal Financial Officer, Principal Accounting Officer, Senior Vice President - Finance (Age 51)
  • Kamalam Unninayar, Chief Financial Officer
  • Maria D. Stahl, Senior Vice President, General Counsel (Age 44)
  • Larry Tsai M.D, Chief Medical Officer
  • Jeffrey A. Chodakewitz M.D., Director (Age 61)
  • Geraldine A. Henwood Ph.D., Director (Age 61)
  • Garen G. Bohlin, Independent Director (Age 69)
  • John G. Freund M.D., Independent Director (Age 63)

Who owns Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.84%), Millennium Management LLC (5.26%), Broadfin Capital LLC (1.72%), Renaissance Technologies LLC (1.15%), Candriam Luxembourg S.C.A. (0.98%) and Hudson Bay Capital Management LP (0.97%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals.

Who sold Tetraphase Pharmaceuticals stock? Who is selling Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Wells Fargo & Company MN and Broadfin Capital LLC. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

Who bought Tetraphase Pharmaceuticals stock? Who is buying Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Renaissance Technologies LLC, Deutsche Bank AG, Candriam Luxembourg S.C.A., Virtus Fund Advisers LLC, Two Sigma Investments LP and Paloma Partners Management Co. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

How do I buy Tetraphase Pharmaceuticals stock?

Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $2.12.

How big of a company is Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals has a market capitalization of $109.38 million and generates $5.14 million in revenue each year. The biopharmaceutical company earns $-77,480,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis. Tetraphase Pharmaceuticals employs 66 workers across the globe.

How can I contact Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]


MarketBeat Community Rating for Tetraphase Pharmaceuticals (TTPH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  452
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.802.802.60
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.83$17.00$17.00$11.75
Price Target Upside: 99.51% upside191.10% upside167.30% upside68.82% upside

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Consensus Price Target History

Price Target History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018SunTrust BanksReiterated RatingBuy$10.00MediumView Rating Details
2/14/2018Stifel NicolausLower Price TargetBuy -> Buy$13.00 -> $6.00N/AView Rating Details
2/14/2018BMO Capital MarketsDowngradeOutperform -> Market Perform$24.00N/AView Rating Details
2/14/2018Piper Jaffray CompaniesReiterated RatingOverweight$8.00N/AView Rating Details
2/14/2018HC WainwrightLower Price TargetBuy -> Buy$17.00 -> $6.00N/AView Rating Details
2/12/2018B. RileyInitiated CoverageBuy -> Buy$11.00HighView Rating Details
9/17/2017Needham & Company LLCReiterated RatingHoldHighView Rating Details
11/4/2016WedbushReiterated RatingNeutral$4.00N/AView Rating Details
5/16/2016GabelliReiterated RatingNeutralN/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Earnings History and Estimates Chart

Earnings by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals (NASDAQ TTPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($0.64)N/AView Earnings Details
11/2/2017Q3 2017($0.63)($0.63)$1.59 million$4.10 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.76)($0.83)$1.54 million$1.59 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.60)($0.79)$1.46 million$1.48 millionViewN/AView Earnings Details
3/8/2017Q4($0.60)($0.61)$1.28 million$1.09 millionViewListenView Earnings Details
11/3/2016($0.50)($0.58)$1.58 million$0.90 millionViewN/AView Earnings Details
8/4/2016Q2($0.46)($0.47)$2.05 million$1.20 millionViewN/AView Earnings Details
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details
3/5/2015($0.54)($0.69)$2.74 million$3.07 millionViewN/AView Earnings Details
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details
3/6/2014($0.46)($0.49)$2.24 million$1.90 millionViewN/AView Earnings Details
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.18)($0.26)$2.41 million$3.72 millionViewN/AView Earnings Details
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Earnings Estimates

2018 EPS Consensus Estimate: ($2.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.67)($0.67)($0.67)
Q2 20181($0.68)($0.68)($0.68)
Q3 20181($0.66)($0.66)($0.66)
Q4 20181($0.63)($0.63)($0.63)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 56.34%
Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2018Jacques DumasInsiderSell8,750$6.22$54,425.008,750View SEC Filing  
1/9/2018Jacques DumasInsiderSell7,167$6.21$44,507.07View SEC Filing  
11/29/2017L Patrick GageDirectorBuy3,880$6.45$25,026.0038,880View SEC Filing  
10/31/2017Jacques DumasInsiderSell8,750$6.03$52,762.508,750View SEC Filing  
8/22/2017Jacques DumasInsiderSell17,500$6.00$105,000.0017,500View SEC Filing  
8/17/2017Jacques DumasInsiderSell7,155$5.86$41,928.30View SEC Filing  
3/15/2017L Patrick GageDirectorBuy11,000$7.49$82,390.0035,000View SEC Filing  
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.0052,000View SEC Filing  
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.0025,000View SEC Filing  
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.005,000View SEC Filing  
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.5417,242View SEC Filing  
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.5091,993View SEC Filing  
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.0028,736View SEC Filing  
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.5296,503View SEC Filing  
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16101,009View SEC Filing  
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.4240,230View SEC Filing  
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tetraphase Pharmaceuticals (NASDAQ TTPH) News Headlines

Source:
DateHeadline
Tetraphase Pharmaceuticals (TTPH) Given Overweight Rating at Piper Jaffray CompaniesTetraphase Pharmaceuticals (TTPH) Given Overweight Rating at Piper Jaffray Companies
www.americanbankingnews.com - February 18 at 6:54 AM
SunTrust Banks Comments on Tetraphase Pharmaceuticals Incs FY2017 Earnings (TTPH)SunTrust Banks Comments on Tetraphase Pharmaceuticals Inc's FY2017 Earnings (TTPH)
www.americanbankingnews.com - February 16 at 6:22 AM
Tetraphase Pharmaceuticals Inc (TTPH) Forecasted to Earn FY2017 Earnings of ($2.80) Per ShareTetraphase Pharmaceuticals Inc (TTPH) Forecasted to Earn FY2017 Earnings of ($2.80) Per Share
www.americanbankingnews.com - February 16 at 6:22 AM
Tetraphase Pharmaceuticals Inc Expected to Post FY2022 Earnings of $0.58 Per Share (TTPH)Tetraphase Pharmaceuticals Inc Expected to Post FY2022 Earnings of $0.58 Per Share (TTPH)
www.americanbankingnews.com - February 15 at 4:28 PM
Here's Why Tetraphase Pharmaceuticals Crashed 60.4% TodayHere's Why Tetraphase Pharmaceuticals Crashed 60.4% Today
finance.yahoo.com - February 15 at 8:37 AM
Tetraphase Pharmaceuticals (TTPH) Cut to Market Perform at BMO Capital MarketsTetraphase Pharmaceuticals (TTPH) Cut to Market Perform at BMO Capital Markets
www.americanbankingnews.com - February 15 at 12:52 AM
Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6.00Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6.00
www.americanbankingnews.com - February 14 at 8:52 PM
Tetraphase Pharmaceuticals (TTPH) Rating Reiterated by SunTrust BanksTetraphase Pharmaceuticals (TTPH) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - February 14 at 4:54 PM
INVESTOR ALERT: Investigation of Tetraphase Pharmaceuticals Announced by Holzer & HolzerINVESTOR ALERT: Investigation of Tetraphase Pharmaceuticals Announced by Holzer & Holzer
finance.yahoo.com - February 14 at 4:54 PM
Tetraphase Pharma (TTPH) IGNITE3 Phase 3 Clinical Trial of Eravacycline in cUTI Failed to Meet Co-Primary EndpointsTetraphase Pharma (TTPH) IGNITE3 Phase 3 Clinical Trial of Eravacycline in cUTI Failed to Meet Co-Primary Endpoints
www.streetinsider.com - February 14 at 9:17 AM
Here’s What’s Moving TetraphaseHere’s What’s Moving Tetraphase
finance.yahoo.com - February 14 at 9:17 AM
HC Wainwright Cuts Tetraphase Pharmaceuticals (TTPH) Price Target to $6.00HC Wainwright Cuts Tetraphase Pharmaceuticals (TTPH) Price Target to $6.00
www.americanbankingnews.com - February 14 at 7:12 AM
Equities Analysts Offer Predictions for Tetraphase Pharmaceuticals Incs FY2017 Earnings (TTPH)Equities Analysts Offer Predictions for Tetraphase Pharmaceuticals Inc's FY2017 Earnings (TTPH)
www.americanbankingnews.com - February 14 at 6:06 AM
Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)
finance.yahoo.com - February 13 at 4:19 PM
Tetraphase Pharmaceuticals (TTPH) Now Covered by Analysts at B. RileyTetraphase Pharmaceuticals (TTPH) Now Covered by Analysts at B. Riley
www.americanbankingnews.com - February 12 at 11:52 PM
Tetraphase Pharmaceuticals Inc (TTPH) Given Consensus Rating of "Hold" by BrokeragesTetraphase Pharmaceuticals Inc (TTPH) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 12 at 1:32 AM
Tetraphase Pharmaceuticals Sees Unusually Large Options Volume (TTPH)Tetraphase Pharmaceuticals Sees Unusually Large Options Volume (TTPH)
www.americanbankingnews.com - February 9 at 1:10 AM
HC Wainwright Reaffirms Buy Rating for Tetraphase Pharmaceuticals (TTPH)HC Wainwright Reaffirms Buy Rating for Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - February 6 at 10:30 PM
Russell 2000 Headed 10% Higher, If Analysts Got The Components Right - NasdaqRussell 2000 Headed 10% Higher, If Analysts Got The Components Right - Nasdaq
www.nasdaq.com - February 5 at 4:17 PM
-$0.64 EPS Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter-$0.64 EPS Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter
www.americanbankingnews.com - February 2 at 7:08 PM
Tetraphase Pharmaceuticals (TTPH) Rating Lowered to Sell at BidaskClubTetraphase Pharmaceuticals (TTPH) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - February 2 at 6:22 AM
Tetraphase Pharmaceuticals Inc (TTPH) Insider Sells $54,425.00 in StockTetraphase Pharmaceuticals Inc (TTPH) Insider Sells $54,425.00 in Stock
www.americanbankingnews.com - January 31 at 6:56 PM
Zacks: Analysts Expect Tetraphase Pharmaceuticals Inc (TTPH) Will Announce Quarterly Sales of $2.26 MillionZacks: Analysts Expect Tetraphase Pharmaceuticals Inc (TTPH) Will Announce Quarterly Sales of $2.26 Million
www.americanbankingnews.com - January 18 at 4:36 AM
Tetraphase Pharmaceuticals Inc (TTPH) Receives Consensus Rating of "Hold" from AnalystsTetraphase Pharmaceuticals Inc (TTPH) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 18 at 1:08 AM
-$0.64 Earnings Per Share Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter-$0.64 Earnings Per Share Expected for Tetraphase Pharmaceuticals Inc (TTPH) This Quarter
www.americanbankingnews.com - January 16 at 7:54 PM
Tetraphase Pharmaceuticals (TTPH) Upgraded at Zacks Investment ResearchTetraphase Pharmaceuticals (TTPH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 13 at 12:42 AM
Jacques Dumas Sells 7,167 Shares of Tetraphase Pharmaceuticals Inc (TTPH) StockJacques Dumas Sells 7,167 Shares of Tetraphase Pharmaceuticals Inc (TTPH) Stock
www.americanbankingnews.com - January 11 at 7:00 PM
Investors Purchase High Volume of Call Options on Tetraphase Pharmaceuticals (TTPH)Investors Purchase High Volume of Call Options on Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - January 7 at 2:40 AM
Zacks Investment Research Lowers Tetraphase Pharmaceuticals (TTPH) to SellZacks Investment Research Lowers Tetraphase Pharmaceuticals (TTPH) to Sell
www.americanbankingnews.com - January 6 at 6:32 AM
Contrasting Tetraphase Pharmaceuticals (TTPH) and Abbott Laboratories (ABT)Contrasting Tetraphase Pharmaceuticals (TTPH) and Abbott Laboratories (ABT)
www.americanbankingnews.com - January 5 at 9:16 PM
Pre-Open Movers 01/03: (SCG) (HGSH) (TRVN) Higher; (CYH) (MGI) (D) Lower (more...)Pre-Open Movers 01/03: (SCG) (HGSH) (TRVN) Higher; (CYH) (MGI) (D) Lower (more...)
www.streetinsider.com - January 3 at 3:32 PM
A Peek Into The Markets: US Stock Futures Rise Ahead Of Fed Minutes - BenzingaA Peek Into The Markets: US Stock Futures Rise Ahead Of Fed Minutes - Benzinga
www.benzinga.com - January 3 at 10:57 AM
5 Stocks To Watch For January 3, 2018 - Benzinga5 Stocks To Watch For January 3, 2018 - Benzinga
www.benzinga.com - January 3 at 10:57 AM
AKAO Faces FDA In June, TECH Opens Wallet, FPRXs FIGHT ... - NasdaqAKAO Faces FDA In June, TECH Opens Wallet, FPRX's FIGHT ... - Nasdaq
www.nasdaq.com - January 3 at 10:57 AM
Tetraphase Pharma (TTPH) Names Larry Tsai MD as Chief Medical Officer - StreetInsider.comTetraphase Pharma (TTPH) Names Larry Tsai MD as Chief Medical Officer - StreetInsider.com
www.streetinsider.com - January 3 at 10:57 AM
3 Stocks to Watch on Wednesday: Moneygram International Inc (MGI), Trevena Inc (TRVN) and Tetraphase ... - Investorplace.com3 Stocks to Watch on Wednesday: Moneygram International Inc (MGI), Trevena Inc (TRVN) and Tetraphase ... - Investorplace.com
investorplace.com - January 3 at 10:57 AM
Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline forTetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for
www.nasdaq.com - January 2 at 8:46 PM
Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
finance.yahoo.com - January 2 at 8:46 PM
After-hours buzz: MGI, TTPH & moreAfter-hours buzz: MGI, TTPH & more
finance.yahoo.com - January 2 at 8:46 PM
Tetraphase Pharmaceuticals Appoints Larry Tsai, M.D. to Chief Medical OfficerTetraphase Pharmaceuticals Appoints Larry Tsai, M.D. to Chief Medical Officer
finance.yahoo.com - January 2 at 8:46 PM
Technical Perspectives on pSivida, Tetraphase Pharma, Lannett, and Catalent - PR Newswire (press release)Technical Perspectives on pSivida, Tetraphase Pharma, Lannett, and Catalent - PR Newswire (press release)
www.prnewswire.com - January 2 at 11:13 AM
-$0.64 EPS Expected for Tetraphase Pharmaceuticals, Inc. (TTPH) This Quarter-$0.64 EPS Expected for Tetraphase Pharmaceuticals, Inc. (TTPH) This Quarter
www.americanbankingnews.com - December 31 at 1:30 AM
Tetraphase Pharmaceuticals (TTPH) & Johnson & Johnson (JNJ) Critical ReviewTetraphase Pharmaceuticals (TTPH) & Johnson & Johnson (JNJ) Critical Review
www.americanbankingnews.com - December 29 at 11:30 PM
Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : December 29, 2017Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : December 29, 2017
finance.yahoo.com - December 29 at 3:33 PM
Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : December 28, 2017Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : December 28, 2017
finance.yahoo.com - December 28 at 10:05 AM
Head-To-Head Contrast: Tetraphase Pharmaceuticals (TTPH) & Galena Biopharma (GALE)Head-To-Head Contrast: Tetraphase Pharmaceuticals (TTPH) & Galena Biopharma (GALE)
www.americanbankingnews.com - December 26 at 11:30 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Given Average Recommendation of "Hold" by BrokeragesTetraphase Pharmaceuticals, Inc. (TTPH) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 24 at 1:31 AM
 Analysts Expect Tetraphase Pharmaceuticals, Inc. (TTPH) Will Announce Quarterly Sales of $2.26 Million Analysts Expect Tetraphase Pharmaceuticals, Inc. (TTPH) Will Announce Quarterly Sales of $2.26 Million
www.americanbankingnews.com - December 16 at 2:26 PM
Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology IndexTetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index
finance.yahoo.com - December 15 at 11:15 AM
Tetraphase Pharmaceuticals (TTPH) & Sanofi (SNY) Financial ComparisonTetraphase Pharmaceuticals (TTPH) & Sanofi (SNY) Financial Comparison
www.americanbankingnews.com - December 11 at 11:22 PM

SEC Filings

Tetraphase Pharmaceuticals (NASDAQ:TTPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tetraphase Pharmaceuticals (NASDAQ TTPH) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.